Has Brent Martin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,426 in general payments to Brent Martin, MD across 273 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brent Martin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brent Martin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brent Martin, MD

MOHS-Micrographic Surgery · Laguna Hills, CANPI 1972990869

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 273 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.

$7,426in general payments, 2019–2025

Across 273 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Johnson & Johnson$783
UCB, Inc.$660
Amgen$570
Incyte Corporation$554
Galderma Laboratories, L.p.$466
plus $3K from 18 others

What the payments were for

Food & beverage$7,35499%
Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	90	$1,697
Johnson & Johnson	20	$783
UCB, Inc.	16	$660
Amgen	32	$570
Incyte Corporation	19	$554
Galderma Laboratories, L.p.	3	$466
Sanofi	4	$388
Regeneron Healthcare Solutions, Inc.	11	$346
Lilly USA, LLC	7	$317
Pfizer	14	$252
E.r. Squibb & Sons, L.L.C.	2	$248
Dermavant Sciences, Inc.	4	$195
Mayne Pharma Commercial LLC	16	$190
Ortho Dermatologics, A Division Of Bausch Health US, LLC	12	$190
Arcutis Biotherapeutics, Inc.	3	$160
LEO Pharma Inc.	7	$144
Novartis	2	$45
VYNE Pharmaceuticals Inc.	2	$43
Biofrontera Inc.	2	$41
Sun Pharmaceutical Industries Inc.	2	$40
Almirall LLC	2	$39
Boehringer Ingelheim	1	$21
Journey Medical Corporation	1	$18
AstraZeneca	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$734
Tremfya$361
Bimzelx$359
NEMLUVIO$318
OPZELURA$255
Sotyktu$248
TALTZ$233
Otezla$145
VTAMA$143
BOTOX$135
Rinvoq$120

How this compares

$7,426 in reported general payments places this provider in the 80th percentile of 144 mohs-micrographic surgery providers in California.

See all mohs-micrographic surgery providers in California →

Medicare billing

Part B allowed, 2024

$262,855

Medicare patients

317

Services billed

2,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	22	$84,926
Taltz SyringeIxekizumab	12	$81,657
Tacrolimus	23	$2,434
Ketoconazole	113	$1,585
Mupirocin	239	$1,395
Fluorouracil	17	$1,357
Clobetasol Propionate	46	$1,275
Cephalexin	180	$776
Fluocinonide	25	$763
Triamcinolone Acetonide	66	$504
Clindamycin Phosphate	27	$499
Nystatin	22	$396
Doxycycline Hyclate	32	$359
Metronidazole	17	$347
Hydrocortisone	22	$60

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Laguna Hills

Sarah ArronBurlingame$98K
Daniel Zelacla Jolla$43K
Ralph MasseySanta Monica$38K
Michael MortazieOrange$29K
Sumaira AasiStanford$27K
Andrea WilleySacramento$21K
Benjamin Kelleyla Jolla$20K
Frank NoodlemanSaratoga$19K
Howard FeinRolling Hills Estates$19K
Joanna ChanLong Beach$18K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →